Targeting Low-Density Lipoprotein AND Dysmetabolism in Type 2 Diabetes Mellitus

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

(2014) Maria J. Gutierrez et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lifestyle and Metformin Treatment Favorably Influence Lipoprotein Subfraction Distribution in the Diabetes Prevention Program

(2013) R. Goldberg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

(2013) Sergey Filippov et al.   JOURNAL OF LIPID RESEARCH

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

(2013) Christie M. Ballantyne et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

(2012) Stephen L. Pinkosky et al.   JOURNAL OF LIPID RESEARCH

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

(2012) Paul M Ridker et al.   LANCET

Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial

(2009) D. K. Coletta et al.   DIABETOLOGIA

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

(2009)   LANCET